Drug Trial Radar · NCT05537987
Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 30, 2021
Primary completion
Nov 2023
Study completion Jul 2024
Sponsor
- Lead sponsor
- InnoCare Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
During this study, dose escalation will be conducted in subjects with advanced solid tumors who have experienced treatment failure after clinical standard of care treatments or who currently have no effective treatment available to evaluate the safety, tolerability, and PK of ICP-723
Conditions
- Advanced Solid Tumors
Interventions
ICP-723Drug
3+3 dose escalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Frequency of dose interruptions, reductions and intensityTime frame: through study completion, an average of 1.5 years.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Kansas Medical / Cancer Centers
Kansas City, Kansas
NYU-Langone Medical Center
New York, New York
Northwest Medical Specialties
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.